The experts on Wednesday afternoon's panel will review clinical data on carfilzomib as a treatment for advanced multiple myeloma patients who are no longer responding to currently approved medicines. The FDA is asking the panel to vote on whether or not to recommend the approval of carfilzomib.
Carfilzomib, which will be sold under the brand name Kyprolis, shrank tumors in 22% of multiple myeloma patients but FDA, in its review, questioned whether cardiovascular and lung-related side effects undermine the drug's benefit."Since carfilzomib produced an ORR
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts